Comparison of Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy Versus Percutaneous Radiofrequency Ablation (Thermoablation)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02859753 |
Recruitment Status : Unknown
Verified July 2016 by Centre Hospitalier Universitaire Dijon.
Recruitment status was: Recruiting
First Posted : August 9, 2016
Last Update Posted : August 9, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Thermoablation Chronic Liver Disease Hepatocellular Carcinoma | Other: Percutaneous Radiofrequency Ablation Other: Percutaneous Microwave Ablation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 156 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Official Title: | Prospective Randomized Controlled Study Comparing Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy (MCT) Versus Percutaneous Radiofrequency Ablation (RFA) in Patients With Chronic Liver Disease and Hepatocellular Carcinoma |
Study Start Date : | January 2014 |
Estimated Primary Completion Date : | October 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: RFA |
Other: Percutaneous Radiofrequency Ablation |
Active Comparator: MCT |
Other: Percutaneous Microwave Ablation |
- Time to disease progression according to American Society of Interventional Radiology criteria [ Time Frame: Through study completion up to 5 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient who have been informed about the research and given their oral consent
- Patients with national health insurance cover
- Patients ≥ 18 years
- ≤ 3 CHC lesions ≤ 4 cm, with a maximum of 3 lesions with a diagnosis of HCC based on histology, or according to European Society for the Study of the Liver (EASL) criteria
- Chronic liver disease or cirrhosis with a Child-Pugh score between 5 and 8 points
- Contra-indication for surgical resection at the time of the therapeutic decision made during a multidisciplinary meeting
Exclusion Criteria:
- Informed consent not obtained (refusal of patient or patient lacking discernment)
- Kidney failure with creatinine clearance < 30 ml/min thus preventing the injection of contrast for the initial or follow-up radiological imaging
- Presence of a malignant tumour other than the HCC at the time of the diagnosis, unless a basocellular carcinoma
- Cirrhosis with a Child-Pugh score > 8
- Contra-indication for percutaneous treatment according to Barcelona Clinic Liver Cancer (BCLC) criteria
- Patients without national health insurance cover

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02859753
Contact: Boris GUIU | 03.80.29.36.86 ext 33 | boris.guiu@chu-dijon.fr |
France | |
CHU Dijon Bourgogne | Recruiting |
Dijon, France, 21079 | |
Contact: Boris GUIU 03 80 29 36 86 ext 33 boris.guiu@chu-dijon.fr |
Responsible Party: | Centre Hospitalier Universitaire Dijon |
ClinicalTrials.gov Identifier: | NCT02859753 |
Other Study ID Numbers: |
GUIU MicroS 2012 |
First Posted: | August 9, 2016 Key Record Dates |
Last Update Posted: | August 9, 2016 |
Last Verified: | July 2016 |
Carcinoma Carcinoma, Hepatocellular Liver Diseases Recurrence Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms |
Adenocarcinoma Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Disease Attributes Pathologic Processes |